(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Mbx Biosciences's earnings in 2026 is -$145,095,000.On average, 12 Wall Street analysts forecast MBX's earnings for 2026 to be -$155,245,347, with the lowest MBX earnings forecast at -$182,000,142, and the highest MBX earnings forecast at -$144,425,247. On average, 12 Wall Street analysts forecast MBX's earnings for 2027 to be -$201,117,805, with the lowest MBX earnings forecast at -$224,337,074, and the highest MBX earnings forecast at -$178,474,548.
In 2028, MBX is forecast to generate -$220,116,291 in earnings, with the lowest earnings forecast at -$279,813,053 and the highest earnings forecast at -$80,815,571.